Hansen Medical to Present at UBS 2012 Global Life Sciences Conference
13 9월 2012 - 5:01AM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that President and CEO,
Bruce Barclay, is scheduled to present at the UBS 2012 Global Life
Sciences Conference. The conference is being held September 19-20,
2012, at the Grand Hyatt in New York, NY. Hansen Medical is
scheduled to present on Wednesday, September 19, 2012, at 3:00 p.m.
Eastern Time.
Hansen Medical will provide a live webcast of the audio
presentation. Interested parties may access the live webcast by
visiting the investor relations section of Hansen Medical's web
site at www.hansenmedical.com. A replay of the webcast will be
available on the site after the presentation.
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, is the global leader in
intravascular robotics, developing products and technology designed
to enable the accurate positioning, manipulation and control of
catheters and catheter-based technologies. The Company's Magellan™
Robotic System, NorthStar™ Robotic Catheter and related
accessories, which are intended to facilitate navigation to
anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union, and the U.S. In the European
Union, the Company's Sensei® X Robotic Catheter System and Artisan
Control Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx® Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S. the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the
U.S. Food and Drug Administration for manipulation and control of
certain mapping catheters in EP procedures. In the United States,
the Sensei System is not approved for use in guiding ablation
procedures; this use remains experimental. The U.S. product
labeling therefore provides that the safety and effectiveness of
the Sensei X System and Artisan Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established. Additional information can
be found at www.hansenmedical.com.
Forward-Looking Statements This press
release contains forward-looking statements regarding, among other
things, statements relating to goals, plans, objectives, milestones
and future events. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words "plan," "expects," "potential," "believes," "goal,"
"estimate," "anticipates," and similar words. These statements are
based on the current estimates and assumptions of our management as
of the date of this press release and are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this
press release. Examples of such statements include statements about
the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for
the sales cycle for newly introduced products; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to maintain our remedial
actions over previously reported material weaknesses in internal
controls over financial reporting; our ability to manage expenses
and cash flow, and obtain additional financing; and other risks
more fully described in the "Risk Factors" section of our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2012 filed with
the SEC on August 9, 2012 and the risks discussed in our other
reports filed with the SEC. Given these uncertainties, you should
not place undue reliance on the forward-looking statements in this
press release. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the
future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024